nach oben

Cancer and Metastasis Reviews

Erschienen in:

01.06.2012 | NON-THEMATIC REVIEW

Regulation of p53 by ING family members in suppression of tumor initiation and progression

verfasst von: Seyed Mehdi Jafarnejad, Gang Li

Erschienen in: Cancer and Metastasis Reviews | Ausgabe 1-2/2012

Einloggen, um Zugang zu erhalten

Abstract

The INhibitor of Growth (ING) family is an evolutionarily conserved set of proteins, implicated in suppression of initiation and progression of cancers in various tissues. They promote cell cycle arrest, cellular senescence and apoptosis, participate in stress responses, regulate DNA replication and DNA damage responses, and inhibit cancer cell migration, invasion, and angiogenesis of the tumors. At the molecular level, ING proteins are believed to participate in chromatin remodeling and transcriptional regulation of their target genes. However, the best known function of ING proteins is their cooperation with p53 tumor suppressor protein in tumor suppression. All major isoforms of ING family members can promote the transactivition of p53 and the majority of them are shown to directly interact with p53. In addition, ING proteins are thought to interact with and modulate the function of auxiliary members of p53 pathway, such as MDM2, ARF , p300, and p21, indicating their widespread involvement in the regulation and function of this prominent tumor suppressor pathway. It seems that p53 pathway is the main mechanism by which ING proteins exert their functions. Nevertheless, regulation of other pathways which are not relevant to p53, yet important for tumorigenesis such as TGF-β and NF-κB, by ING proteins is also observed. This review summarizes the current understanding of the mutual interactions and cooperation between different members of ING family with p53 pathway and implications of this cooperation in the suppression of cancer initiation and progression.

Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: the next generation. Cell, 144(5), 646–674.PubMedCrossRef

Franco, O. E., Shaw, A. K., Strand, D. W., & Hayward, S. W. (2009). Cancer associated fibroblasts in cancer pathogenesis. Semin Cell Dev Biol, 21(1), 33–39.PubMed

Malkin, D., Li, F. P., Strong, L. C., Fraumeni, J. F., Nelson, C. E., Kim, D. H., et al. (1990). Germ line P53 mutations in a familial syndrome of breast-cancer, sarcomas, and other neoplasms. Science, 250(4985), 1233–1238.PubMedCrossRef

Esteller, M., & Lujambio, A. (2007). CpG island hypermethylation of tumor suppressor microRNAs in human cancer. Cell Cycle, 6(12), 1455–1459.PubMed

Cairns, P., Okami, K., Halachmi, S., Halachmi, N., Esteller, M., Herman, J. G., et al. (1997). Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. Cancer Research, 57(22), 4997–5000.PubMed

Mietz, J. A., Unger, T., Huibregtse, J. M., & Howley, P. M. (1992). The transcriptional transactivation function of wild-type p53 is inhibited by SV40 large T-antigen and by HPV-16 E6 oncoprotein. EMBO Journal, 11(13), 5013–5020.PubMed

Bischof, O., Nacerddine, K., & Dejean, A. (2005). Human papillomavirus oncoprotein E7 targets the promyelocytic leukemia protein and circumvents cellular senescence via the Rb and p53 tumor suppressor pathways. Molecular Cellular Biology, 25(3), 1013–1024.CrossRef

Kastan, M. B., Canman, C. E., & Leonard, C. J. (1995). P53, cell cycle control and apoptosis: implications for cancer. Cancer Metastasis Reviews, 14(1), 3–15.PubMedCrossRef

Meek, D. W. (2009). Tumour suppression by p53: a role for the DNA damage response? Nature Reviews Cancer, 9(10), 714–723.PubMed

10.

Helton, E. S., & Chen, X. (2007). p53 modulation of the DNA damage response. Journal of Cellular Biochemistry, 100(4), 883–896.PubMedCrossRef

11.

Sablina, A. A., Budanov, A. V., Ilyinskaya, G. V., Agapova, L. S., Kravchenko, J. E., & Chumakov, P. M. (2005). The antioxidant function of the p53 tumor suppressor. Nature Medicine, 11(12), 1306–1313.PubMedCrossRef

12.

Polyak, K., Xia, Y., Zweier, J. L., Kinzler, K. W., & Vogelstein, B. (1997). A model for p53-induced apoptosis. Nature, 389(6648), 300–305.PubMedCrossRef

13.

Van Meir, E. G., Polverini, P. J., Chazin, V. R., Su Huang, H. J., de Tribolet, N., & Cavenee, W. K. (1994). Release of an inhibitor of angiogenesis upon induction of wild type p53 expression in glioblastoma cells. Nature Genetics, 8(2), 171–176.PubMedCrossRef

14.

Eastham, J. A., Grafton, W., Martin, C. M., & Williams, B. J. (2000). Suppression of primary tumor growth and the progression to metastasis with p53 adenovirus in human prostate cancer. Journal of Urology, 164(3 Pt 1), 814–819.PubMed

15.

Muller, P. A., Vousden, K. H., & Norman, J. C. (2011). p53 and its mutants in tumor cell migration and invasion. Journal of Cell Biology, 192(2), 209–218.PubMedCrossRef

16.

Chang, C. J., Chao, C. H., Xia, W. Y., Yang, J. Y., Xiong, Y., Li, C. W., et al. (2011). p53 regulates epithelial–mesenchymal transition and stem cell properties through modulating miRNAs. Nature Cell Biology, 13(3), 317–U296.PubMedCrossRef

17.

Smith, M. L., Chen, I. T., Zhan, Q., O'Connor, P. M., & Fornace, A. J., Jr. (1995). Involvement of the p53 tumor suppressor in repair of u.v.-type DNA damage. Oncogene, 10(6), 1053–1059.PubMed

18.

Yin, Y., Terauchi, Y., Solomon, G. G., Aizawa, S., Rangarajan, P. N., Yazaki, Y., et al. (1998). Involvement of p85 in p53-dependent apoptotic response to oxidative stress. Nature, 391(6668), 707–710.PubMedCrossRef

19.

Friedman, P. N., Chen, X. B., Bargonetti, J., & Prives, C. (1993). The p53 protein is an unusually shaped tetramer that binds directly to DNA. Proceedings of the National Academy of Sciences of the United States of America, 90(8), 3319–3323.PubMedCrossRef

20.

Joerger, A. C., & Fersht, A. R. (2008). Structural biology of the tumor suppressor p53. Annual Review of Biochemistry, 77, 557–582.PubMedCrossRef

21.

Wahl, G. M., Wang, Y. Y. V., Leblanc, M., Fox, N., Mao, J. H., Tinkum, K. L., et al. (2011). Fine-tuning p53 activity through C-terminal modification significantly contributes to HSC homeostasis and mouse radiosensitivity. Genes & Development, 25(13), 1426–1438.CrossRef

22.

Webley, K., Bond, J. A., Jones, C. J., Blaydes, J. P., Craig, A., Hupp, T., et al. (2000). Posttranslational modifications of p53 in replicative senescence overlapping but distinct from those induced by DNA damage. Molecular and Cellular Biology, 20(8), 2803–2808.PubMedCrossRef

23.

Xu, Y., Feng, L. J., Lin, T. X., Uranishi, H., & Gu, W. (2005). Functional analysis of the roles of posttranslational modifications at the p53 C terminus in regulating p53 stability and activity. Molecular and Cellular Biology, 25(13), 5389–5395.PubMedCrossRef

24.

Shvarts, A., Steegenga, W. T., Riteco, N., vanLaar, T., Dekker, P., Bazuine, M., et al. (1996). MDMX: a novel p53-binding protein with some functional properties of MDM2. EMBO Journal, 15(19), 5349–5357.PubMed

25.

Haupt, Y., Maya, R., Kazaz, A., & Oren, M. (1997). Mdm2 promotes the rapid degradation of p53. Nature, 387(6630), 296–299.PubMedCrossRef

26.

Vousden, K. H., Ashcroft, M., & Taya, Y. (2000). Stress signals utilize multiple pathways to stabilize p53. Molecular and Cellular Biology, 20(9), 3224–3233.PubMedCrossRef

27.

Prives, C., Shieh, S. Y., Ahn, J., Tamai, K., & Taya, Y. (2000). The human homologs of checkpoint kinases Chk1 and Cds1 (Chk2) phosphorylate p53 at multiple DNA damage-inducible sites. Genes & Development, 14(3), 289–300.

28.

Avantaggiati, M. L., Ogryzko, V., Gardner, K., Giordano, A., Levine, A. S., & Kelly, K. (1997). Recruitment of p300/CBP in p53-dependent signal pathways. Cell, 89(7), 1175–1184.PubMedCrossRef

29.

Xu, Y. (2003). Regulation of p53 responses by post-translational modifications. Cell Death and Differentiation, 10(4), 400–403.PubMedCrossRef

30.

Jackson, J. G., & Pereira-Smith, O. M. (2006). p53 is preferentially recruited to the promoters of growth arrest genes p21 and GADD45 during replicative senescence of normal human fibroblasts. Cancer Research, 66(17), 8356–8360.PubMedCrossRef

31.

el-Deiry, W. S. (1998). Regulation of p53 downstream genes. Seminars in Cancer Biology, 8(5), 345–357.PubMedCrossRef

32.

Sherr, C. J., & Roberts, J. M. (1999). CDK inhibitors: positive and negative regulators of G1-phase progression. Genes & Development, 13(12), 1501–1512.CrossRef

33.

Hanas, J. S., Lerner, M. R., Lightfoot, S. A., Raczkowski, C., Kastens, D. J., Brackett, D. J., et al. (1999). Expression of the cyclin-dependent kinase inhibitor p21(WAF1/CIP1) and p53 tumor suppressor in dysplastic progression and adenocarcinoma in Barrett esophagus. Cancer, 86(5), 756–763.PubMedCrossRef

34.

Yang, H., Zhao, R., & Lee, M. H. (2006). 14-3-3sigma, a p53 regulator, suppresses tumor growth of nasopharyngeal carcinoma. Molecular Cancer Therapeutics, 5(2), 253–260.PubMedCrossRef

35.

Yu, J., & Zhang, L. (2005). The transcriptional targets of p53 in apoptosis control. Biochemical and Biophysical Research Communications, 331(3), 851–858.PubMedCrossRef

36.

Baptiste-Okoh, N., Barsotti, A. M., & Prives, C. (2008). A role for caspase 2 and PIDD in the process of p53-mediated apoptosis. Proceedings of the National Academy of Sciences of the United States of America, 105(6), 1937–1942.PubMedCrossRef

37.

Kannan, K., Amariglio, N., Rechavi, G., & Givol, D. (2000). Profile of gene expression regulated by induced p53: connection to the TGF-beta family. FEBS Letters, 470(1), 77–82.PubMedCrossRef

38.

Dameron, K. M., Volpert, O. V., Tainsky, M. A., & Bouck, N. (1994). Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science, 265(5178), 1582–1584.PubMedCrossRef

39.

Nishimori, H., Shiratsuchi, T., Urano, T., Kimura, Y., Kiyono, K., Tatsumi, K., et al. (1997). A novel brain-specific p53-target gene, BAI1, containing thrombospondin type 1 repeats inhibits experimental angiogenesis. Oncogene, 15(18), 2145–2150.PubMedCrossRef

40.

Garkavtsev, I., Kazarov, A., Gudkov, A., & Riabowol, K. (1996). Suppression of the novel growth inhibitor p33ING1 promotes neoplastic transformation. Nature Genetics, 14(4), 415–420.PubMedCrossRef

41.

Nagashima, M., Shiseki, M., Miura, K., Hagiwara, K., Linke, S. P., Pedeux, R., et al. (2001). DNA damage-inducible gene p33ING2 negatively regulates cell proliferation through acetylation of p53. Proceedings of the National Academy of Sciences of the United States of America, 98(17), 9671–9676.PubMedCrossRef

42.

Nagashima, M., Shiseki, M., Pedeux, R. M., Okamura, S., Kitahama-Shiseki, M., Miura, K., et al. (2003). A novel PHD-finger motif protein, p47ING3, modulates p53-mediated transcription, cell cycle control, and apoptosis. Oncogene, 22(3), 343–350.PubMedCrossRef

43.

Shiseki, M., Nagashima, M., Pedeux, R. M., Kitahama-Shiseki, M., Miura, K., Okamura, S., et al. (2003). p29ING4 and p28ING5 bind to p53 and p300, and enhance p53 activity. Cancer Research, 63(10), 2373–2378.PubMed

44.

Gunduz, M., Ouchida, M., Fukushima, K., Ito, S., Jitsumori, Y., Nakashima, T., et al. (2002). Allelic loss and reduced expression of the ING3, a candidate tumor suppressor gene at 7q31, in human head and neck cancers. Oncogene, 21(28), 4462–4470.PubMedCrossRef

45.

Vieyra, D., Toyama, T., Hara, Y., Boland, D., Johnston, R., & Riabowol, K. (2002). ING1 isoforms differentially affect apoptosis in a cell age-dependent manner. Cancer Research, 62(15), 4445–4452.PubMed

46.

Shi, X., & Gozani, O. (2005). The fellowships of the INGs. Journal of Cellular Biochemistry, 96(6), 1127–1136.PubMedCrossRef

47.

Zeremski, M., Hill, J. E., Kwek, S. S. S., Grigorian, I. A., Gurova, K. V., Garkavtsev, I. V., et al. (1999). Structure and regulation of the mouse ing1 gene—three alternative transcripts encode two PHD finger proteins that have opposite effects on p53 function. The Journal of Biological Chemistry, 274(45), 32172–32181.PubMedCrossRef

48.

He, G. H., Helbing, C. C., Wagner, M. J., Sensen, C. W., & Riabowol, K. (2005). Phylogenetic analysis of the ING family of PHD finger proteins. Molecular and Biological Evolution, 22(1), 104–116.CrossRef

49.

Ythier, D., Larrieu, D., Brambilla, C., Brambilla, E., & Pedeux, R. (2008). The new tumor suppressor genes ING: genomic structure and status in cancer. International Journal of Cancer, 123(7), 1483–1490.CrossRef

50.

Mellor, J. (2006). It takes a PHD to read the histone code. Cell, 126(1), 22–24.PubMedCrossRef

51.

Baker, L. A., Allis, C. D., & Wang, G. G. (2008). PHD fingers in human diseases: disorders arising from misinterpreting epigenetic marks. Mutation Research, 647(1–2), 3–12.PubMed

52.

Wang, Y., Dai, D. L., Martinka, M., & Li, G. (2007). Prognostic significance of nuclear ING3 expression in human cutaneous melanoma. Clinical Cancer Research, 13(14), 4111–4116.PubMedCrossRef

53.

Zheng, H. C., Xia, P., Xu, X. Y., Takahashi, H., & Takano, Y. (2011). The nuclear to cytoplasmic shift of ING5 protein during colorectal carcinogenesis with their distinct links to pathologic behaviors of carcinomas. Human Pathology, 42(3), 424–433.PubMedCrossRef

54.

Li, X. H., Nishida, T., Noguchi, A., Zheng, Y., Takahashi, H., Yang, X. H., et al. (2010). Decreased nuclear expression and increased cytoplasmic expression of ING5 may be linked to tumorigenesis and progression in human head and neck squamous cell carcinoma. Journal of Cancer Research and Clinical Oncology, 136(10), 1573–1583.PubMedCrossRef

55.

Nouman, G. S., Angus, B., Lunec, J., Crosier, S., Lodge, A., & Anderson, J. J. (2002). Comparative assessment expression of the inhibitor of growth 1 gene (ING1) in normal and neoplastic tissues. Hybridoma and Hybridomics, 21(1), 1–10.PubMedCrossRef

56.

Vieyra, D., Senger, D. L., Toyama, T., Muzik, H., Brasher, P. M., Johnston, R. N., et al. (2003). Altered subcellular localization and low frequency of mutations of ING1 in human brain tumors. Clinical Cancer Research, 9(16 Pt 1), 5952–5961.PubMed

57.

Gong, W., Russell, M., Suzuki, K., & Riabowol, K. (2006). Subcellular targeting of p33ING1b by phosphorylation-dependent 14-3-3 binding regulates p21WAF1 expression. Molecular and Cellular Biology, 26(8), 2947–2954.PubMedCrossRef

58.

Scott, M., Boisvert, F. M., Vieyra, D., Johnston, R. N., Bazett-Jones, D. P., & Riabowol, K. (2001). UV induces nucleolar translocation of ING1 through two distinct nucleolar targeting sequences. Nucleic Acids Research, 29(10), 2052–2058.PubMedCrossRef

59.

Garate, M., Campos, E. I., Bush, J. A., Xiao, H., & Li, G. (2007). Phosphorylation of the tumor suppressor p33(ING1b) at Ser-126 influences its protein stability and proliferation of melanoma cells. The FASEB Journal, 21(13), 3705–3716.CrossRef

60.

Wagner, M. J., & Helbing, C. C. (2005). Multiple variants of the ING1 and ING2 tumor suppressors are differentially expressed and thyroid hormone-responsive in Xenopus laevis. General and Comparative Endocrinology, 144(1), 38–50.PubMedCrossRef

61.

Osaki, M., Nagahama, Y., Ishimaru, M., Inoue, T., Maeda, A., Nakada, C., et al. (2008). Apoptotic pathway induced by transduction of RUNX3 in the human gastric carcinoma cell line MKN-1. Cancer Science, 99(1), 23–30.PubMed

62.

Cheung, K. J. J., Bush, J. A., Jia, W., & Li, G. (2000). Expression of the novel tumour suppressor p33(ING1) is independent of p53. British Journal of Cancer, 83(11), 1468–1472.PubMedCrossRef

63.

Harris, C. C., Kumamoto, K., Spillare, E. A., Fujita, K., Horikawa, I., Yamashita, T., et al. (2008). Nutlin-3a activates p53 to both down-regulate inhibitor of growth 2 and up-regulate mir-34a, mir-34b, and mir-34c expression, and induce senescence. Cancer Research, 68(9), 3193–3203.PubMedCrossRef

64.

Li, G., Garate, M., Campos, E. I., Bush, J. A., & Xiao, H. (2007). Phosphorylation of the tumor suppressor p33(ING1b) at Ser-126 influences its protein stability and proliferation of melanoma cells. The FASEB Journal, 21(13), 3705–3716.CrossRef

65.

Li, G., Garate, M., Wong, R. P. C., Campos, E. I., & Wang, Y. M. (2008). NAD(P)H quinone oxidoreductase 1 inhibits the proteasomal degradation of the tumour suppressor p33(ING1b). EMBO Reports, 9(6), 576–581.PubMedCrossRef

66.

Kameyama, K., Huang, C. L., Liu, D., Masuya, D., Nakashima, T., Sumitomo, S., et al. (2003). Reduced ING1b gene expression plays an important role in carcinogenesis of non-small cell lung cancer patients. Clinical Cancer Research, 9(13), 4926–4934.PubMed

67.

Shen, D. H., Chan, K. Y., Khoo, U. S., Ngan, H. Y., Xue, W. C., Chiu, P. M., et al. (2005). Epigenetic and genetic alterations of p33ING1b in ovarian cancer. Carcinogenesis, 26(4), 855–863.PubMedCrossRef

68.

Yu, G. Z., Zhu, M. H., Zhu, Z., Ni, C. R., Zheng, J. M., & Li, F. M. (2004). Genetic alterations and reduced expression of tumor suppressor p33(ING1b) in human exocrine pancreatic carcinoma. World Journal of Gastroenterology, 10(24), 3597–3601.PubMed

69.

Takahashi, M., Ozaki, T., Todo, S., & Nakagawara, A. (2004). Decreased expression of the candidate tumor suppressor gene ING1 is associated with poor prognosis in advanced neuroblastomas. Oncology Reports, 12(4), 811–816.PubMed

70.

Tallen, G., Kaiser, I., Krabbe, S., Lass, U., Hartmann, C., Henze, G., et al. (2004). NoING1 mutations in human brain tumours but reduced expression in high malignancy grades of astrocytoma. International Journal of Cancer, 109(3), 476–479.CrossRef

71.

Piche, B., & Li, G. (2010). Inhibitor of growth tumor suppressors in cancer progression. Cellular and Molecular Life Sciences, 67(12), 1987–1999.PubMedCrossRef

72.

Cengiz, B., Gunduz, E., Gunduz, M., Beder, L. B., Tamamura, R., Bagci, C., et al. (2010). Tumor-specific mutation and downregulation of ING5 detected in oral squamous cell carcinoma. International Journal of Cancer, 127(9), 2088–2094.CrossRef

73.

Gunduz, M., Nagatsuka, H., Demircan, K., Gunduz, E., Cengiz, B., Ouchida, M., et al. (2005). Frequent deletion and down-regulation of ING4, a candidate tumor suppressor gene at 12p13, in head and neck squamous cell carcinomas. Gene, 356, 109–117.PubMedCrossRef

74.

Coles, A. H., & Jones, S. N. (2009). The ING gene family in the regulation of cell growth and tumorigenesis. Journal of Cellular Physiology, 218(1), 45–57.PubMedCrossRef

75.

Li, J., Wang, Y., Wong, R. P., & Li, G. (2009). The role of ING tumor suppressors in UV stress response and melanoma progression. Current Drug Targets, 10(5), 455–464.PubMedCrossRef

76.

Bua, D. J., & Binda, O. (2009). The return of the INGs, histone mark sensors and phospholipid signaling effectors. Current Drug Targets, 10(5), 418–431.PubMedCrossRef

77.

Garkavtsev, I., & Riabowol, K. (1997). Extension of the replicative life span of human diploid fibroblasts by inhibition of the p33ING1 candidate tumor suppressor. Molecular and Cellular Biology, 17(4), 2014–2019.PubMed

78.

Abad, M., Moreno, A., Palacios, A., Narita, M., Blanco, F., Moreno-Bueno, G., et al. (2011). The tumor suppressor ING1 contributes to epigenetic control of cellular senescence. Aging Cell, 10(1), 158–171.PubMedCrossRef

79.

Larrieu, D., Ythier, D., Brambilla, C., & Pedeux, R. (2010). ING2 controls the G1 to S-phase transition by regulating p21 expression. Cell Cycle, 9(19), 3984–3990.PubMedCrossRef

80.

Kim, S., Welm, A. L., & Bishop, J. M. (2010). A dominant mutant allele of the ING4 tumor suppressor found in human cancer cells exacerbates MYC-initiated mouse mammary tumorigenesis. Cancer Research, 70(12), 5155–5162.PubMedCrossRef

81.

Li, X., Cai, L., Chen, H., Zhang, Q., Zhang, S., Wang, Y., et al. (2009). Inhibitor of growth 4 induces growth suppression and apoptosis in glioma U87MG. Pathobiology, 76(4), 181–192.PubMedCrossRef

82.

Cai, L., Li, X., Zheng, S., Wang, Y., Li, H., Yang, J., et al. (2009). Inhibitor of growth 4 is involved in melanomagenesis and induces growth suppression and apoptosis in melanoma cell line M14. Melanoma Research, 19(1), 1–7.PubMedCrossRef

83.

Pedeux, R., Sengupta, S., Shen, J. C., Demidov, O. N., Saito, S., Onogi, H., et al. (2005). ING2 regulates the onset of replicative senescence by induction of p300-dependent p53 acetylation. Molecular and Cellular Biology, 25(15), 6639–6648.PubMedCrossRef

84.

Gniadecki, R., Hansen, M., & Wulf, H. C. (1997). Two pathways for induction of apoptosis by ultraviolet radiation in cultured human keratinocytes. The Journal of Investigative Dermatology, 109(2), 163–169.PubMedCrossRef

85.

Shimizu, S., Eguchi, Y., Kamiike, W., Itoh, Y., Hasegawa, J., Yamabe, K., et al. (1996). Induction of apoptosis as well as necrosis by hypoxia and predominant prevention of apoptosis by Bcl-2 and Bcl-X(L). Cancer Research, 56(9), 2161–2166.PubMed

86.

Yang, C. S., Yang, G. Y., Liao, J., Kim, K., & Yurkow, E. J. (1998). Inhibition of growth and induction of apoptosis in human cancer cell lines by tea polyphenols. Carcinogenesis, 19(4), 611–616.PubMedCrossRef

87.

Hansson, M., Asea, A., Ersson, U., Hermodsson, S., & Hellstrand, K. (1996). Induction of apoptosis in NK cells by monocyte-derived reactive oxygen metabolites. The Journal of Immunology, 156(1), 42–47.PubMed

88.

Elmore, S. (2007). Apoptosis: a review of programmed cell death. Toxicologic Pathology, 35(4), 495–516.PubMedCrossRef

89.

Shah, S., & Riabowol, K. (2009). Signaling pathways of the ING proteins in apoptosis. Current Drug Targets, 10(5), 385–391.PubMedCrossRef

90.

Shah, S., Smith, H., Feng, X., Rancourt, D. E., & Riabowol, K. (2009). ING function in apoptosis in diverse model systems. Biochemistry and Cell Biology, 87(1), 117–125.PubMedCrossRef

91.

Helbing, C. C., Veillette, C., Riabowol, K., Johnston, R. N., & Garkavtsev, I. (1997). A novel candidate tumor suppressor, ING1, is involved in the regulation of apoptosis. Cancer Research, 57(7), 1255–1258.PubMed

92.

Scott, M., Bonnefin, P., Vieyra, D., Boisvert, F. M., Young, D., Bazett-Jones, D. P., et al. (2001). UV-induced binding of ING1 to PCNA regulates the induction of apoptosis. Journal of Cell Science, 114(19), 3455–3462.PubMed

93.

Cheung, K. J., Jr., & Li, G. (2002). p33(ING1) enhances UVB-induced apoptosis in melanoma cells. Experimental Cell Research, 279(2), 291–298.PubMedCrossRef

94.

Wang, Y., & Li, G. (2006). ING3 promotes UV-induced apoptosis via Fas/caspase-8 pathway in melanoma cells. The Journal of Biological Chemistry, 281(17), 11887–11893.PubMedCrossRef

95.

Li, Z., Xie, Y., Sheng, W., Miao, J., Xiang, J., & Yang, J. (2010). Tumor-suppressive effect of adenovirus-mediated inhibitor of growth 4 gene transfer in breast carcinoma cells in vitro and in vivo. Cancer Biotherapy and Radiopharmaceuticals, 25(4), 427–437.PubMedCrossRef

96.

Xie, Y., Sheng, W., Miao, J., Xiang, J., & Yang, J. (2011). Enhanced antitumor activity by combining an adenovirus harboring ING4 with cisplatin for hepatocarcinoma cells. Cancer Gene Therapy, 18(3), 176–188.PubMedCrossRef

97.

Chin, M. Y., Ng, K. C., & Li, G. (2005). The novel tumor suppressor p33ING2 enhances UVB-induced apoptosis in human melanoma cells. Experimental Cell Research, 304(2), 531–543.PubMedCrossRef

98.

Negrini, S., Gorgoulis, V. G., & Halazonetis, T. D. (2010). Genomic instability—an evolving hallmark of cancer. Nature Reviews Molecular Cell Biology, 11(3), 220–228.PubMedCrossRef

99.

Charames, G. S., & Bapat, B. (2003). Genomic instability and cancer. Current Molecular Medicine, 3(7), 589–596.PubMedCrossRef

100.

Kichina, J. V., Zeremski, M., Aris, L., Gurova, K. V., Walker, E., Franks, R., et al. (2006). Targeted disruption of the mouse ing1 locus results in reduced body size, hypersensitivity to radiation and elevated incidence of lymphomas. Oncogene, 25(6), 857–866.PubMedCrossRef

101.

Vieyra, D., Loewith, R., Scott, M., Bonnefin, P., Boisvert, F. M., Cheema, P., et al. (2002). Human ING1 proteins differentially regulate histone acetylation. The Journal of Biological Chemistry, 277(33), 29832–29839.PubMedCrossRef

102.

Feng, X., Hara, Y., & Riabowol, K. (2002). Different HATS of the ING1 gene family. Trends in Cell Biology, 12(11), 532–538.PubMedCrossRef

103.

Kuzmichev, A., Zhang, Y., Erdjument-Bromage, H., Tempst, P., & Reinberg, D. (2002). Role of the Sin3-histone deacetylase complex in growth regulation by the candidate tumor suppressor p33(ING1). Molecular and Cellular Biology, 22(3), 835–848.PubMedCrossRef

104.

Doyon, Y., Cayrou, C., Ullah, M., Landry, A. J., Cote, V., Selleck, W., et al. (2006). ING tumor suppressor proteins are critical regulators of chromatin acetylation required for genome expression and perpetuation. Molecular Cell, 21(1), 51–64.PubMedCrossRef

105.

Allard, S., Masson, J. Y., & Cote, J. (2004). Chromatin remodeling and the maintenance of genome integrity. Biochimica et Biophysica Acta, 1677(1–3), 158–164.PubMed

106.

Wang, J., Chin, M. Y., & Li, G. (2006). The novel tumor suppressor p33ING2 enhances nucleotide excision repair via inducement of histone H4 acetylation and chromatin relaxation. Cancer Research, 66(4), 1906–1911.PubMedCrossRef

107.

Kuo, W. H., Wang, Y., Wong, R. P., Campos, E. I., & Li, G. (2007). The ING1b tumor suppressor facilitates nucleotide excision repair by promoting chromatin accessibility to XPA. Experimental Cell Research, 313(8), 1628–1638.PubMedCrossRef

108.

Wong, R. P., Lin, H., Khosravi, S., Piche, B., Jafarnejad, S. M., Chen, D. W., et al. (2011). Tumour suppressor ING1b maintains genomic stability upon replication stress. Nucleic Acids Res (in press)

109.

Toyama, T., Iwase, H., Watson, P., Muzik, H., Saettler, E., Magliocco, A., et al. (1999). Suppression of ING1 expression in sporadic breast cancer. Oncogene, 18(37), 5187–5193.PubMedCrossRef

110.

Ahmed, I. A., Kelly, S. B., Anderson, J. J., Angus, B., Challen, C., & Lunec, J. (2008). The predictive value of p53 and p33(ING1b) in patients with Dukes' C colorectal cancer. Colorectal Disease, 10(4), 344–351.PubMedCrossRef

111.

Nouman, G. S., Anderson, J. J., Mathers, M. E., Leonard, N., Crosier, S., Lunec, J., et al. (2002). Nuclear to cytoplasmic compartment shift of the p33ING1b tumour suppressor protein is associated with malignancy in melanocytic lesions. Histopathology, 40(4), 360–366.PubMedCrossRef

112.

Zhang, J. T., Wang, D. W., Li, Q. X., Zhu, Z. L., Wang, M. W., Cui, D. S., et al. (2008). Nuclear to cytoplasmic shift of p33(ING1b) protein from normal oral mucosa to oral squamous cell carcinoma in relation to clinicopathological variables. Journal of Cancer Research and Clinical Oncology, 134(3), 421–426.PubMedCrossRef

113.

Tallen, G., Farhangi, S., Tamannai, M., Holtkamp, N., Mangoldt, D., Shah, S., et al. (2009). The inhibitor of growth 1 (ING1) proteins suppress angiogenesis and differentially regulate angiopoietin expression in glioblastoma cells. Oncology Research, 18(2–3), 95–105.PubMedCrossRef

114.

Coles, A. H., Liang, H., Zhu, Z., Marfella, C. G., Kang, J., Imbalzano, A. N., et al. (2007). Deletion of p37Ing1 in mice reveals a p53-independent role for Ing1 in the suppression of cell proliferation, apoptosis, and tumorigenesis. Cancer Research, 67(5), 2054–2061.PubMedCrossRef

115.

Cheung, K. J., Jr., & Li, G. (2002). The tumour suppressor p33ING1 does not enhance camptothecin-induced cell death in melanoma cells. International Journal of Oncology, 20(6), 1319–1322.PubMed

116.

Abad, M., Menendez, C., Fuchtbauer, A., Serrano, M., Fuchtbauer, E. M., & Palmero, I. (2007). Ing1 mediates p53 accumulation and chromatin modification in response to oncogenic stress. The Journal of Biological Chemistry, 282(42), 31060–31067.PubMedCrossRef

117.

Li, J., Martinka, M., & Li, G. (2008). Role of ING4 in human melanoma cell migration, invasion and patient survival. Carcinogenesis, 29(7), 1373–1379.PubMedCrossRef

118.

Li, M., Jin, Y., Sun, W. J., Yu, Y., Bai, J., Tong, D. D., et al. (2009). Reduced expression and novel splice variants of ING4 in human gastric adenocarcinoma. The Journal of Pathology, 219(1), 87–95.PubMedCrossRef

119.

Kim, S., Chin, K., Gray, J. W., & Bishop, J. M. (2004). A screen for genes that suppress loss of contact inhibition: identification of ING4 as a candidate tumor suppressor gene in human cancer. Proceedings of the National Academy of Sciences of the United States of America, 101(46), 16251–16256.PubMedCrossRef

120.

Moreno, A., Palacios, A., Orgaz, J. L., Jimenez, B., Blanco, F. J., & Palmero, I. (2010). Functional impact of cancer-associated mutations in the tumor suppressor protein ING4. Carcinogenesis, 31(11), 1932–1938.PubMedCrossRef

121.

Hung, T., Binda, O., Champagne, K. S., Kuo, A. J., Johnson, K., Chang, H. Y., et al. (2009). ING4 mediates crosstalk between histone H3 K4 trimethylation and H3 acetylation to attenuate cellular transformation. Molecular Cell, 33(2), 248–256.PubMedCrossRef

122.

Semenza, G. L. (2003). Targeting HIF-1 for cancer therapy. Nature Reviews. Cancer, 3(10), 721–732.PubMedCrossRef

123.

Li, J., & Li, G. (2010). Cell cycle regulator ING4 is a suppressor of melanoma angiogenesis that is regulated by the metastasis suppressor BRMS1. Cancer Research, 70(24), 10445–10453.PubMedCrossRef

124.

Harris, C. C., Kumamoto, K., Fujita, K., Kurotani, R., Saito, M., Unoki, M., et al. (2009). ING2 is upregulated in colon cancer and increases invasion by enhanced MMP13 expression. International Journal of Cancer, 125(6), 1306–1315.CrossRef

125.

Garkavtsev, I., Grigorian, I. A., Ossovskaya, V. S., Chernov, M. V., Chumakov, P. M., & Gudkov, A. V. (1998). The candidate tumour suppressor p33ING1 cooperates with p53 in cell growth control. Nature, 391(6664), 295–298.PubMedCrossRef

126.

Shinoura, N., Muramatsu, Y., Nishimura, M., Yoshida, Y., Saito, A., Yokoyama, T., et al. (1999). Adenovirus-mediated transfer of p33ING1 with p53 drastically augments apoptosis in gliomas. Cancer Research, 59(21), 5521–5528.PubMed

127.

Luo, Z. G., Tang, H., Li, B., Zhu, Z., Ni, C. R., & Zhu, M. H. (2011). Genetic alterations of tumor suppressor ING1 in human non-small cell lung cancer. Oncology Reports, 25(4), 1073–1081.PubMed

128.

Shimada, H., Liu, T. L., Ochiai, T., Shimizu, T., Haupt, Y., Hamada, H., et al. (2002). Facilitation of adenoviral wild-type p53-induced apoptotic cell death by overexpression of p33(ING1) in T.Tn human esophageal carcinoma cells. Oncogene, 21(8), 1208–1216.PubMedCrossRef

129.

Leung, K. M., Po, L. S., Tsang, F. C., Sin, W. Y., Lau, A., Ho, H. T. B., et al. (2002). The candidate tumor suppressor ING1b can stabilize p53 by disrupting the regulation of p53 by MDM2. Cancer Research, 62(17), 4890–4893.PubMed

130.

Tsang, F. C., Po, L. S., Leung, K. M., Lau, A., Siu, W. Y., & Poon, R. Y. C. (2003). ING1b decreases cell proliferation through p53-dependent and -independent mechanisms. FEBS Letters, 553(3), 277–285.PubMedCrossRef

131.

Lin, Y. L., Sengupta, S., Gurdziel, K., Bell, G. W., Jacks, T., & Flores, E. R. (2009). p63 and p73 transcriptionally regulate genes involved in DNA repair. Plos Genetics, 5(10), e1000680.

132.

Yao, J. Y., & Chen, J. K. (2010). TAp63 plays compensatory roles in p53-deficient cancer cells under genotoxic stress. Biochemical and Biophysical Research Communications, 403(3–4), 310–315.PubMedCrossRef

133.

Vayssade, M., Haddada, H., Faridoni-Laurens, L., Tourpin, S., Valent, A., Benard, J., et al. (2005). p73 functionally replaces 1353 in adriamycin-treated, p53-deficient breast cancer cells. International Journal of Cancer, 116(6), 860–869.CrossRef

134.

Cheung, K. J., Jr., Mitchell, D., Lin, P., & Li, G. (2001). The tumor suppressor candidate p33(ING1) mediates repair of UV-damaged DNA. Cancer Research, 61(13), 4974–4977.PubMed

135.

Wong, R. P., Lin, H., Khosravi, S., Piche, B., Jafarnejad, S. M., Chen, D. W., et al. (2011). Tumour suppressor ING1b maintains genomic stability upon replication stress. Nucleic Acids Research, 39(9), 3632–3642.PubMedCrossRef

136.

Avkin, S., Sevilya, Z., Toube, L., Geacintov, N., Chaney, S. G., Oren, M., et al. (2006). p53 and p21 regulate error-prone DNA repair to yield a lower mutation load. Molecular Cell, 22(3), 407–413.PubMedCrossRef

137.

Yang, X. H., Shiotani, B., Classon, M., & Zou, L. (2008). Chk1 and Claspin potentiate PCNA ubiquitination. Genes & Development, 22(9), 1147–1152.CrossRef

138.

Ou, Y. H., Chung, P. H., Sun, T. P., & Shieh, S. Y. (2005). p53 C-terminal phosphorylation by CHK1 and CHK2 participates in the regulation of DNA-damage-induced C-terminal acetylation. Molecular Biology of the Cell, 16(4), 1684–1695.PubMedCrossRef

139.

Zhu, Z., Lin, J., Qu, J. H., Feitelson, M. A., Ni, C. R., Li, F. M., et al. (2005). Inhibitory effect of tumor suppressor p33(ING1b) and its synergy with p53 gene in hepatocellular carcinoma. World Journal of Gastroenterology, 11(13), 1903–1909.PubMed

140.

Sherr, C. J., & Weber, J. D. (2000). The ARF/p53 pathway. Current Opinion in Genetics and Development, 10(1), 94–99.PubMedCrossRef

141.

Gonzalez, L., Freije, J. M. P., Cal, S., Lopez-Otin, C., Serrano, M., & Palmero, I. (2006). A functional link between the tumour suppressors ARF and p33ING1. Oncogene, 25(37), 5173–5179.PubMed

142.

Zhu, J. J., Li, F. B., Zhu, X. F., & Liao, W. M. (2006). The p33ING1b tumor suppressor cooperates with p53 to induce apoptosis in response to etoposide in human osteosarcoma cells. Life Sciences, 78(13), 1469–1477.PubMedCrossRef

143.

Zhu, J. J., Li, F. B., Zhou, J. M., Liu, Z. C., Zhu, X. F., & Liao, W. M. (2005). The tumor suppressor p33ING1b enhances taxol-induced apoptosis by p53-dependent pathway in human osteosarcoma U2OS cells. Cancer Biology & Therapy, 4(1), 39–47.CrossRef

144.

Kataoka, H., Bonnefin, P., Vieyra, D., Feng, X. L., Hara, Y., Miura, Y., et al. (2003). ING1 represses transcription by direct DNA binding and through effects on p53. Cancer Research, 63(18), 5785–5792.PubMed

145.

Zhu, Z., Luo, Z., Li, Y., Ni, C., Li, H., & Zhu, M. (2009). Human inhibitor of growth 1 inhibits hepatoma cell growth and influences p53 stability in a variant-dependent manner. Hepatology, 49(2), 504–512.PubMedCrossRef

146.

Tamannai, M., Farhangi, S., Truss, M., Sinn, B., Wurm, R., Bose, P., et al. (2010). The inhibitor of growth 1 (ING1) is involved in trichostatin A-induced apoptosis and caspase 3 signaling in p53-deficient glioblastoma cells. Oncology Research, 18(10), 469–480.PubMedCrossRef

147.

Tallen, U. G., Truss, M., Kunitz, F., Wellmann, S., Unryn, B., Sinn, B., et al. (2008). Down-regulation of the inhibitor of growth 1 (ING1) tumor suppressor sensitizes p53-deficient glioblastoma cells to cisplatin-induced cell death. Journal of Neuro-Oncology, 86(1), 23–30.PubMedCrossRef

148.

Goeman, F., Thormeyer, D., Abad, M., Serrano, M., Schmidt, O., Palmero, I., et al. (2005). Growth inhibition by the tumor suppressor p33ING1 in immortalized and primary cells: involvement of two silencing domains and effect of Ras. Molecular and Cellular Biology, 25(1), 422–431.PubMedCrossRef

149.

Gozani, O., Karuman, P., Jones, D. R., Ivanov, D., Cha, J., Lugovskoy, A. A., et al. (2003). The PHD finger of the chromatin-associated protein ING2 functions as a nuclear phosphoinositide receptor. Cell, 114(1), 99–111.PubMedCrossRef

150.

Wang, Y. M., Wang, J., & Li, G. (2006). Leucine zipper-like domain is required for tumor suppressor ING2-mediated nucleotide excision repair and apoptosis. FEBS Letters, 580(16), 3787–3793.PubMedCrossRef

151.

Sun, G., Jin, S., & Baskaran, R. (2009). MMR/c-Abl-dependent activation of ING2/p73alpha signaling regulates the cell death response to N-methyl-N′-nitro-N-nitrosoguanidine. Experimental Cell Research, 315(18), 3163–3175.PubMedCrossRef

152.

Smith, K. T., Martin-Brown, S. A., Florens, L., Washburn, M. P., & Workman, J. L. (2010). Deacetylase inhibitors dissociate the histone-targeting ING2 subunit from the Sin3 complex. Chemistry and Biology, 17(1), 65–74.PubMedCrossRef

153.

Kumamoto, K., Spillare, E. A., Fujita, K., Horikawa, I., Yamashita, T., Appella, E., et al. (2008). Nutlin-3a activates p53 to both down-regulate inhibitor of growth 2 and up-regulate mir-34a, mir-34b, and mir-34c expression, and induce senescence. Cancer Research, 68(9), 3193–3203.PubMedCrossRef

154.

Harris, S. L., & Levine, A. J. (2005). The p53 pathway: positive and negative feedback loops. Oncogene, 24(17), 2899–2908.PubMedCrossRef

155.

Larrieu, D., Ythier, D., Binet, R., Brambilla, C., Brambilla, E., Sengupta, S., et al. (2009). ING2 controls the progression of DNA replication forks to maintain genome stability. EMBO Reports, 10(10), 1168–1174.PubMedCrossRef

156.

Stark, G. R., Hastak, K., Paul, R. K., Agarwal, M. K., Thakur, V. S., Amin, A. R. M. R., et al. (2008). DNA synthesis from unbalanced nucleotide pools causes limited DNA damage that triggers ATR-CHK1-dependent p53 activation. Proceedings of the National Academy of Sciences of the United States of America, 105(17), 6314–6319.PubMedCrossRef

157.

Shieh, S. Y., Ahn, J., Tamai, K., Taya, Y., & Prives, C. (2000). The human homologs of checkpoint kinases Chk1 and Cds1 (Chk2) phosphorylate p53 at multiple DNA damage-inducible sites. Genes & Development, 14(3), 289–300.

158.

Sarker, K. P., Kataoka, H., Chan, A., Netherton, S. J., Pot, I., Huynh, M. A., et al. (2008). ING2 as a novel mediator of transforming growth factor-beta-dependent responses in epithelial cells. The Journal of Biological Chemistry, 283(19), 13269–13279.PubMedCrossRef

159.

Datto, M. B., Li, Y., Panus, J. F., Howe, D. J., Xiong, Y., & Wang, X. F. (1995). Transforming growth-factor-beta induces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism. Proceedings of the National Academy of Sciences of the United States of America, 92(12), 5545–5549.PubMedCrossRef

160.

Luo, J., Shah, S., Riabowol, K., & Mains, P. E. (2009). The Caenorhabditis elegans ing-3 gene regulates ionizing radiation-induced germ-cell apoptosis in a p53-associated pathway. Genetics, 181(2), 473–482.PubMedCrossRef

161.

Wang, Y. H., Tsay, Y. G., Tan, B. C., Lo, W. Y., & Lee, S. C. (2003). Identification and characterization of a novel p300-mediated p53 acetylation site, lysine 305. The Journal of Biological Chemistry, 278(28), 25568–25576.PubMedCrossRef

162.

Zhang, X., Xu, L. S., Wang, Z. Q., Wang, K. S., Li, N., Cheng, Z. H., et al. (2004). ING4 induces G2/M cell cycle arrest and enhances the chemosensitivity to DNA-damage agents in HepG2 cells. FEBS Letters, 570(1–3), 7–12.PubMedCrossRef

163.

Iizuka, M., Sarmento, O. F., Sekiya, T., Scrable, H., Allis, C. D., & Smith, M. M. (2008). Hbo1 links p53-dependent stress signaling to DNA replication licensing. Molecular and Cellular Biology, 28(1), 140–153.PubMedCrossRef

164.

Saha, A., Bamidele, A., Murakami, M., & Robertson, E. S. (2011). EBNA3C attenuates the function of p53 through interaction with inhibitor of growth family proteins 4 and 5. Journal of Virology, 85(5), 2079–2088.PubMedCrossRef

165.

Zhang, X., Wang, K. S., Wang, Z. Q., Xu, L. S., Wang, Q. W., Chen, F., et al. (2005). Nuclear localization signal of ING4 plays a key role in its binding to p53. Biochemical and Biophysical Research Communications, 331(4), 1032–1038.PubMedCrossRef

166.

Unoki, M., Shen, J. C., Zheng, Z. M., & Harris, C. C. (2006). Novel splice variants of ING4 and their possible roles in the regulation of cell growth and motility. The Journal of Biological Chemistry, 281(45), 34677–34686.PubMedCrossRef

167.

Guo, Q., & Fast, W. (2011). Citrullination of inhibitor of growth 4 (ING4) by peptidylarginine deminase 4 (PAD4) disrupts the interaction between ING4 and p53. The Journal of Biological Chemistry, 286(19), 17069–17078.PubMedCrossRef

168.

Chang, X. T., Han, J. X., Pang, L., Zhao, Y., Yang, Y., & Shen, Z. L. (2009). Increased PADI4 expression in blood and tissues of patients with malignant tumors. Bmc Cancer, 9(40).

169.

Slack, J. L., Causey, C. P., & Thompson, P. R. (2011). Protein arginine deiminase 4: a target for an epigenetic cancer therapy. Cellular and Molecular Life Sciences, 68(4), 709–720.PubMedCrossRef

170.

Raho, G., Miranda, C., Tamborini, E., Pierotti, M. A., & Greco, A. (2007). Detection of novel mRNA splice variants of human ING4 tumor suppressor gene. Oncogene, 26(36), 5247–5257.PubMedCrossRef

171.

Garkavtsev, I., Kozin, S. V., Chernova, O., Xu, L., Winkler, F., Brown, E., et al. (2004). The candidate tumour suppressor protein ING4 regulates brain tumour growth and angiogenesis. Nature, 428(6980), 328–332.PubMedCrossRef

172.

Nozell, S., Laver, T., Moseley, D., Nowoslawski, L., DeVos, M., Atkinson, G. P., et al. (2008). The ING4 tumor suppressor attenuates NF-kappa B activity at the promoters of target genes. Molecular and Cellular Biology, 28(21), 6632–6645.PubMedCrossRef

173.

Meylan, E., Dooley, A. L., Feldser, D. M., Shen, L., Turk, E., Ouyang, C., et al. (2009). Requirement for NF-kappaB signalling in a mouse model of lung adenocarcinoma. Nature, 462(7269), 104–107.PubMedCrossRef

174.

Ozer, A., Wu, L. C., & Bruick, R. K. (2005). The candidate tumor suppressor ING4 represses activation of the hypoxia inducible factor (HIF). Proceedings of the National Academy of Sciences of the United States of America, 102(21), 7481–7486.PubMedCrossRef

175.

Li, X. M., Cai, L. M., Liang, M. H., Wang, Y. D., Yang, J., & Zhao, Y. L. (2008). ING4 induces cell growth inhibition in human lung adenocarcinoma A549 cells by means of Wnt-1/beta-catenin signaling pathway. The Anatomical Record: Advances in Integrative Anatomy and Evolutionary Biology, 291(5), 593–600.CrossRef

Titel: Regulation of p53 by ING family members in suppression of tumor initiation and progression
verfasst von: Seyed Mehdi Jafarnejad
Gang Li
Publikationsdatum: 01.06.2012
Verlag: Springer US
Erschienen in: Cancer and Metastasis Reviews / Ausgabe 1-2/2012
Print ISSN: 0167-7659
Elektronische ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-011-9329-5

Neu im Fachgebiet Onkologie

Nodal-negativ nach neoadjuvanter Chemo: Axilladissektion verzichtbar?

03.05.2024 Mammakarzinom Nachrichten

Wenn bei Mammakarzinomen durch eine neoadjuvante Chemotherapie ein Downstaging von nodal-positiv zu nodal-negativ gelingt, scheint es auch ohne Axilladissektion nur selten zu axillären Rezidiven zu kommen.

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Bestrahlung nach Prostatektomie: mehr Schaden als Nutzen?

02.05.2024 Prostatakarzinom Nachrichten

Eine adjuvante Radiotherapie nach radikaler Prostata-Op. bringt den Betroffenen wahrscheinlich keinen Vorteil. Im Gegenteil: Durch die Bestrahlung steigt offenbar das Risiko für Harn- und Stuhlinkontinenz.

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

IT für Ärzte Nachrichten

Darauf haben viele Praxen gewartet: Das Zi hat eine Liste von Praxisverwaltungssystemen veröffentlicht, die von Nutzern positiv bewertet werden. Eine gute Grundlage für wechselwillige Ärzte und Psychotherapeuten.

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Regulation of p53 by ING family members in suppression of tumor initiation and progression

Abstract

Neu im Fachgebiet Onkologie

Nodal-negativ nach neoadjuvanter Chemo: Axilladissektion verzichtbar?

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

Bestrahlung nach Prostatektomie: mehr Schaden als Nutzen?

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

Update Onkologie

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1-2/2012

Inappropriate gene expression in human cancer and its far-reaching biological and clinical significance

Starvation tactics for solid tumors: tumor blood flow interruption via a combretastatin derivative (Cderiv), and its microcirculation mechanism

Cancer stem cells and EMT in carcinoma

Cancer-associated-fibroblasts and tumour cells: a diabolic liaison driving cancer progression

Potential molecular targets for inhibiting bone invasion by oral squamous cell carcinoma: a review of mechanisms

Gastroenteropancreatic neuroendocrine tumor cancer stem cells: do they exist?

Neu im Fachgebiet Onkologie

Nodal-negativ nach neoadjuvanter Chemo: Axilladissektion verzichtbar?

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

Bestrahlung nach Prostatektomie: mehr Schaden als Nutzen?

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

Update Onkologie